These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35239000)

  • 1. BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience.
    Stefoni V; Argnani L; Carella M; Casadei B; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Coppola PE; Zinzani PL
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):1043-1047. PubMed ID: 35239000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
    Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Salvi F; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Carlo-Stella C
    J Clin Oncol; 2016 Sep; 34(27):3293-9. PubMed ID: 27382096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.
    Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Zanni M; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Ricci F; Carlo-Stella C
    Blood Adv; 2020 Jan; 4(1):136-140. PubMed ID: 31935284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients.
    Gokmen A; Sahin U; Soydan E; Gokgoz Z; Okcu MK; Ozan U; Arslan O; Ilhan O; Ozcan M
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e885-e892. PubMed ID: 35927182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
    Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peritransplant Radiation Therapy in Patients With Refractory or Relapsed Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant: Long-Term Results of a Retrospective Study of the Fondazione Italiana Linfomi.
    Levis M; Campbell BA; Matrone F; Grapulin L; Di Russo A; Buglione M; Iamundo De Cumis I; Simontacchi G; Ciammella P; Magli A; Pascale G; Meregalli S; MacManus M; Fanetti G; De Felice F; Furfaro G; Ciccone G; Ricardi U
    Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1008-1018. PubMed ID: 36822373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy and peripheral hematopoietic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma.
    Kelta M; Zekri J; Abdelghany E; Rehman JU; Khan ZA; Al-Saadi R; Dada R
    Tumori; 2018 Dec; 104(6):471-475. PubMed ID: 28009428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
    LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
    Blood; 2018 Jul; 132(1):40-48. PubMed ID: 29703778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
    Suyanı E; Sucak GT; Akı ŞZ; Yeğin ZA; Özkurt ZN; Yağcı M
    Ann Hematol; 2011 Jun; 90(6):685-91. PubMed ID: 21072518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
    Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
    Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma.
    Swoboda R; Giebel S; Knopińska-Posłuszny W; Chmielowska E; Drozd-Sokołowska J; Paszkiewicz-Kozik E; Kulikowski W; Taszner M; Mendrek W; Najda J; Czerw T; Olszewska-Szopa M; Czyż A; Giza A; Spychałowicz W; Subocz E; Szwedyk P; Krzywon A; Wilk A; Zaucha JM
    Ann Hematol; 2021 Jul; 100(7):1755-1767. PubMed ID: 33625572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
    Nieto Y; Thall PF; Ma J; Valdez BC; Ahmed S; Anderlini P; Popat U; Jones RB; Shpall EJ; Hosing C; Qazilbash M; Kebriaei P; Alousi A; Timmons M; Gulbis A; Myers A; Oki Y; Fanale M; Dabaja B; Pinnix C; Milgrom S; Champlin R; Andersson BS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1602-1609. PubMed ID: 29501779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
    Czyz A; Lojko-Dankowska A; Dytfeld D; Nowicki A; Gil L; Matuszak M; Kozlowska-Skrzypczak M; Kazmierczak M; Bembnista E; Komarnicki M
    Med Oncol; 2013; 30(3):611. PubMed ID: 23702734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.
    Trippett TM; Schwartz CL; Guillerman RP; Gamis AS; Gardner S; Hogan S; London WB; Chen L; de Alarcon P
    Pediatr Blood Cancer; 2015 Jan; 62(1):60-4. PubMed ID: 25308760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.
    Smeltzer JP; Cashen AF; Zhang Q; Homb A; Dehdashti F; Abboud CN; Dipersio JF; Stockerl-Goldstein KE; Uy GL; Vij R; Westervelt P; Bartlett NL; Fehniger TA
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1646-52. PubMed ID: 21601641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
    Rassy E; Danu A; Ibrahim T; Lazarovici J; Ghez D; Michot JM; Arfi-Rouche J; Rossignol J; Vergé V; Dartigues P; Ribrag V
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e373-e380. PubMed ID: 33277224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma.
    Kuruvilla J; Nagy T; Pintilie M; Tsang R; Keating A; Crump M
    Cancer; 2006 Jan; 106(2):353-60. PubMed ID: 16329112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.